PT - JOURNAL ARTICLE AU - Ahmadi, Armin AU - Gamboa, Jorge AU - Norman, Jennifer E. AU - Enkhmaa, Byambaa AU - Tucker, Madelynn AU - Bennett, Brian J. AU - Zelnick, Leila R. AU - Fan, Sili AU - Berglund, Lars F. AU - Ikizler, Talat Alp AU - de Boer, Ian H. AU - Cummings, Bethany P. AU - Roshanravan, Baback TI - Impaired incretin homeostasis in non-diabetic moderate-severe CKD AID - 10.1101/2023.12.15.23300050 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.15.23300050 4099 - http://medrxiv.org/content/early/2023/12/18/2023.12.15.23300050.short 4100 - http://medrxiv.org/content/early/2023/12/18/2023.12.15.23300050.full AB - Background Incretins are regulators of insulin secretion and glucose homeostasis that are metabolized by dipeptidyl peptidase-4 (DPP-4). Moderate-severe CKD may modify incretin release, metabolism, or response.Methods We performed 2-hour oral glucose tolerance testing (OGTT) in 59 people with non-diabetic CKD (eGFR<60 ml/min per 1.73 m2) and 39 matched controls. We measured total (tAUC) and incremental (iAUC) area under the curve of plasma total glucagon-like peptide-1 (GLP-1) and total glucose-dependent insulinotropic polypeptide (GIP). Fasting DPP-4 levels and activity were measured. Linear regression was used to adjust for demographic, body composition, and lifestyle factors.Results Mean eGFR was 38 ±13 and 89 ±17ml/min per 1.73 m2 in CKD and controls. GLP-1 iAUC and GIP iAUC were higher in CKD than controls with a mean of 1531 ±1452 versus 1364 ±1484 pMxmin, and 62370 ±33453 versus 42365 ±25061 pgxmin/ml, respectively. After adjustment, CKD was associated with 15271 pMxmin/ml greater GIP iAUC (95% CI 387, 30154) compared to controls. Adjustment for covariates attenuated associations of CKD with higher GLP-1 iAUC (adjusted difference, 122, 95% CI -619, 864). Plasma glucagon levels were higher at 30 minutes (mean difference, 1.6, 95% CI 0.3, 2.8 mg/dl) and 120 minutes (mean difference, 0.84, 95% CI 0.2, 1.5 mg/dl) in CKD compared to controls. There were no differences in insulin levels or plasma DPP-4 activity or levels between groups.Conclusion Incretin response to oral glucose is preserved or augmented in moderate-severe CKD, without apparent differences in circulating DPP-4 concentration or activity. However, neither insulin secretion nor glucagon suppression are enhanced.Significance statement CKD is associated with metabolic and physiological disturbances including disturbed glucose and insulin homeostasis. Incretin hormones are potent regulators of insulin secretion and glucose metabolism; however, determinants and potential consequence of incretin response in CKD are incompletely understood. This study revealed that total incretin levels and incretin response during oral glucose tolerance testing (OGTT) were significantly higher among patients with moderate-severe non-diabetic CKD compared to healthy. Unlike in healthy individuals, increased incretin response was not correlated with insulin and C-peptide response to OGTT in CKD. These differences coincided with persistently greater glucagon levels in response to physiological stimuli in CKD. Disruption in the incretin system and glucagon dynamics may contribute to metabolic disturbances in moderate-severe CKD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this study was provided by an unrestricted grant from the Northwest Kidney Centers and R01DK087726 (IHDB), R01DK087726-S1 (IHDB), R01DK129793 (BR), R01DK087726, R01DK087726-S1, K01 DK102851 (JAA, IHDB), R01DK125794 (JLG), K24 DK096574 (TRZ), R56DK124853 (BPC), and P30 DK017047 (University of Washington Diabetes Research Center) and Dialysis Clinics Incorporated, C-4122 (BR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The procedures in the study and informed consent forms were reviewed and approved by the University of Washington Human Subjects Division (HSD).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors